Table 2.
Components and efficacy of seasonal influenza vaccines (USA).
| Year/Season | Vaccine Components* | Vaccine Effectiveness (%)# | |||
|---|---|---|---|---|---|
| H1N1 (Subtype A) | H3N2 (Subtype A) | Subtype B (Yamagata lineage) | Subtype B (Victoria lineage) | ||
| 2015-16 | A/California/7/2009 | A/Switzerland/9715293/2013 | B/Phuket/3073/2013 | - | 48 |
| 2016-17 | A/California/7/2009 | A/Hong Kong/4801/2014 | B/Phuket/3073/2013 | B/Brisbane/60/2008 | 40 |
| 2017-18 | A/Michigan/45/2015$ | A/Hong Kong/4801/2014 | B/Phuket/3073/2013 | B/Brisbane/60/2008 | 38 |
| 2018-19 | A/Michigan/45/2015$ | A/Singapore/INFIMH-16-0019/2016 | B/Phuket/3073/2013 | B/Colorado/06/2017 | 29 |
| 2019-20 | A/Brisbane/02/2018$ | A/Kansas/14/2017 | B/Phuket/3073/2013 | B/Colorado/06/2017 | 39 |
| 2020-21 | A/Guangdong-Maonan/SWL1536/2019$ | A/HongKong/2671/2019 | B/Phuket/3073/2013 | B/Washington/02/2019 | - |
| 2021-22 | A/Victoria/2570/2019$ | A/Cambodia/e0826360/2020 | B/Phuket/3073/2013 | B/Washington/02/2019 | - |
*FDA; #US CDC; $pdmo9-like. - indicates no data available (vaccine effectiveness was not calculated for the 2020-21 vaccine due to low influenza virus circulation).